MedTrace Logo

Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

NCT07550621 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-24

No results posted yet for this study

Summary

A Phase I, open-label, fixed-sequence, two-part drug-drug interaction study in healthy Chinese adults to evaluate the effect of multiple-dose rifampin (Part A) or itraconazole (Part B) on the single-dose pharmacokinetics of MDR-001, an oral GLP-1 receptor agonist.

Conditions

  • Healthy Volunteers (HV)

Interventions

DRUG

MDR-001

Oral small-molecule GLP-1 receptor agonist ;Investigational drug (not yet approved)

DRUG

Rifampin

Strong CYP3A4 inducer; Marketed anti-tuberculosis drug

DRUG

Itraconazole

Strong CYP3A4 inhibitor; Marketed antifungal drug

Sponsors & Collaborators

  • MindRank AI Ltd

    lead INDUSTRY

Principal Investigators

  • Xiaojiao Li, MD · The First Hospital of Jilin University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-06
Primary Completion
2026-05-31
Completion
2026-06-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07550621 on ClinicalTrials.gov